A5111912022- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- PARP inhibition in cancer therapy
- BRCA gene mutations in cancer
- Cancer Treatment and Pharmacology
- Cervical Cancer and HPV Research
- Intraperitoneal and Appendiceal Malignancies
- Reproductive Biology and Fertility
- Colorectal and Anal Carcinomas
- Lung Cancer Treatments and Mutations
- Glioma Diagnosis and Treatment
- Chemotherapy-related skin toxicity
- Multiple and Secondary Primary Cancers
- Lymphoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Sarcoma Diagnosis and Treatment
- Circular RNAs in diseases
- Ovarian function and disorders
- Lung Cancer Research Studies
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Brain Metastases and Treatment
- Immune Cell Function and Interaction
- Acute Myeloid Leukemia Research
- Reproductive System and Pregnancy
European Institute of Oncology
2015-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2020-2024
Ripamonti
2006-2023
University of Brescia
2018
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2018
University of Milan
1996-2011
Mario Negri Institute for Pharmacological Research
2002-2011
University of Milano-Bicocca
2002-2011
Gynecologic Oncology Group
2006-2010
Mylan (Switzerland)
2009
The authors compared clinically based neurotoxicity scales with the Total Neuropathy Scale, aim of improving grading severity chemotherapy-induced peripheral neuropathy (CIPN). CIPN was evaluated in a series 60 women treated cisplatin- and paclitaxel-based chemotherapy. A reduced version TNS (TNSr) also compared. concluded that TNSr can be used to assess effectively, results this evaluation reliably correlated oncologic sensory neurotoxicity.
PURPOSE: To assess the activity, efficacy, and tolerability of single-agent paclitaxel a platinum-containing regimen in previously treated patients with recurrent ovarian cancer. PATIENTS AND METHODS: Patients who achieved complete remission platinum-based regimens whose disease recurred after progression-free interval more than 12 months were included study. Every 21 days, received 175 mg/m2 intravenously (IV) over 3 hours or cyclophosphamide 500 mg/m2, doxorubicin 50 cisplatin (CAP) IV....
Background: In the phase III PAOLA-1 study, addition of maintenance olaparib to bevacizumab in patients with newly diagnosed high-grade ovarian cancer (HGOC) resulted prolonged progression-free survival (PFS), particularly for homologous recombination deficiency-positive tumors, including those a BRCA mutation (BRCAm).The magnitude benefit from and according location BRCA1/BRCA2 remains be explored.Patients methods: Patients advanced-stage HGOC responding after platinum-based chemotherapy þ...
In the PAOLA-1/ENGOT-ov25 trial (NCT02477644), adding maintenance olaparib to bevacizumab provided a substantial progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer and homologous recombination deficiency (HRD)-positive tumors, irrespective of clinical risk. Subsequently, clinically meaningful improvement overall was reported plus HRD-positive subgroup. We report updated by risk HRD status.
Adult granulosa cell tumors represent less than 5% of all ovarian malignancies. The aim this study was to analyze the clinicopathological parameters and their impact on progression-free overall survival.Patients with primary adult treated in three international referral centers between July 1999 December 2018 were included. following data anonymously exported from prospective database: age at diagnosis, International Federation Gynecology Obstetrics (FIGO) stage, adjuvant therapy, surgical...
PURPOSE: To assess the activity, efficacy, and tolerability of single-agent paclitaxel a platinum-containing regimen in previously treated patients with recurrent ovarian cancer. PATIENTS AND METHODS: Patients who achieved complete remission platinum-based regimens whose disease recurred after progression-free interval more than 12 months were included study. Every 21 days, received 175 mg/m 2 intravenously (IV) over 3 hours or cyclophosphamide 500 , doxorubicin 50 cisplatin (CAP) IV....